We unpack the full scope of the U.S. budget cuts, from canceled clinical trials and stalled drug approvals to mass layoffs ...

Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

Discover six hemophilia companies developing new treatments for the genetic bleeding disorder, from gene therapies to RNAi ...

Genome sequencing is the process of determining the complete DNA sequence of an organism’s genome, a step-by-step decoding of all the genetic instructions. In humans, that means reading around 3 ...

Discover how early functional screening at the single-cell level transforms therapeutic development of your antibodies.

Discover why BTK inhibitors have attracted interest for treating multiple sclerosis, as a few late-stage candidates close in ...

Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...

Biotech companies have always been global at their core. From running clinical trials across continents to delivering therapies internationally, success in these industries also depends on crossing ...

Over four decades since its discovery, human immunodeficiency virus (HIV) remains one of the most challenging infectious diseases. Antiretroviral therapy (ART) has turned HIV from a fatal diagnosis ...

A fresh take on gene-editing, centered on engineered recombinases, emerges as Brink Therapeutics, a Paris-based biotech startup, secures €3.5 million ($4 million) in seed funding with Kuma Partners ...